This publication reports on newly diagnosed cancers registered in England in addition to cancer deaths registered in England during 2020. It includes this summary report showing key findings, spreadsheet tables with more detailed estimates, and a methodology document.

Mortality from prostate cancer (ICD-10 C61 equivalent to ICD-9 185). To reduce deaths from prostate cancer. Legacy unique identifier: P00628

This report presents trends in cancer incidence and survival updated with incidence and mortality . Source agency: Cancer Registry Northern Ireland Designation: Official Statistics not designated as National Statistics Language: English Alternative title: Cancer Incidence and Survival Trends in Northern Ireland

Information on the waiting times of patients with suspected cancer and those subsequently diagnosed with cancer Source agency: Health Designation: National Statistics Language: English Alternative title: Statistics on Waiting Times for Suspected and Diagnosed Cancer Patients Annual Report

This statistic shows the number of registrations of newly diagnosed cases of prostate cancer in England in 2022, by age group. Over **** thousand new cases were reported among men aged 70 to 74 years of age in this year.

Legacy unique identifier: P00513

United Kingdom UK: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data was reported at 10.900 % in 2016. This records a decrease from the previous number of 11.200 % for 2015. United Kingdom UK: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data is updated yearly, averaging 12.200 % from Dec 2000 (Median) to 2016, with 5 observations. The data reached an all-time high of 16.400 % in 2000 and a record low of 10.900 % in 2016. United Kingdom UK: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s UK – Table UK.World Bank: Health Statistics. Mortality from CVD, cancer, diabetes or CRD is the percent of 30-year-old-people who would die before their 70th birthday from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g., injuries or HIV/AIDS).; ; World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).; Weighted Average;

The cancer services profiles have been updated to split the existing indicator ‘Females, 25 to 64, attending cervical screening within target period (3.5 or 5.5 year coverage, %)’ by age group (25 to 49 and 50 to 64), creating 2 new and distinct indicators. All other indicators for the cancer services profile were released on 1 December 2020.

These profiles present data at GP, Clinical Commissioning Group (CCG) and national level on:

• cancer incidence and screening
• Two Week Wait (TWW) referrals
• diagnostic services
• emergency presentations and admissions

The https://fingertips.phe.org.uk/profile/cancerservices" class="govuk-link">cancer services profiles have been designed to support commissioners and health professionals to assess the impact of cancer on their local population and make decisions about services.

These profiles replace the GP cancer profiles that were previously presented in the Cancer Commissioning Toolkit.

UK: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Female data was reported at 9.000 NA in 2016. This records a decrease from the previous number of 9.200 NA for 2015. UK: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Female data is updated yearly, averaging 9.800 NA from Dec 2000 (Median) to 2016, with 5 observations. The data reached an all-time high of 12.900 NA in 2000 and a record low of 9.000 NA in 2016. UK: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Female data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s United Kingdom – Table UK.World Bank.WDI: Health Statistics. Mortality from CVD, cancer, diabetes or CRD is the percent of 30-year-old-people who would die before their 70th birthday from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g., injuries or HIV/AIDS).; ; World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).; Weighted average;

Legacy unique identifier: P00232

Legacy unique identifier: P00229

The Organisation for Economic Co-operation and Development (OECD) Health Statistics offers the most comprehensive source of comparable statistics on health and health systems across OECD countries. It is an essential tool for health researchers and policy advisors in governments, the private sector and the academic community, to carry out comparative analyses and draw lessons from international comparisons of diverse health care systems. Within UKDS.Stat the data are presented in the following databases:

Health status

This datasets presents internationally comparable statistics on morbidity and mortality with variables such as life expectancy, causes of mortality, maternal and infant mortality, potential years of life lost, perceived health status, infant health, dental health, communicable diseases, cancer, injuries, absence from work due to illness. The annual data begins in 2000.

Non-medical determinants of health

This dataset examines the non-medical determinants of health by comparing food, alcohol, tobacco consumption and body weight amongst countries. The data are expressed in different measures such as calories, grammes, kilo, gender, population. The data begins in 1960.

Healthcare resources

This dataset includes comparative tables analyzing various health care resources such as total health and social employment, physicians by age, gender, categories, midwives, nurses, caring personnel, personal care workers, dentists, pharmacists, physiotherapists, hospital employment, graduates, remuneration of health professionals, hospitals, hospital beds, medical technology with their respective subsets. The statistics are expressed in different units of measure such as number of persons, salaried, self-employed, per population. The annual data begins in 1960.

Healthcare utilisation

This dataset includes statistics comparing different countries’ level of health care utilisation in terms of prevention, immunisation, screening, diagnostics exams, consultations, in-patient utilisation, average length of stay, diagnostic categories, acute care, in-patient care, discharge rates, transplants, dialyses, ICD-9-CM. The data is comparable with respect to units of measures such as days, percentages, population, number per capita, procedures, and available beds.

Health Care Quality Indicators

This dataset includes comparative tables analyzing various health care quality indicators such as cancer care, care for acute exacerbation of chronic conditions, care for chronic conditions and care for mental disorders. The annual data begins in 1995.

Pharmaceutical market

This dataset focuses on the pharmaceutical market comparing countries in terms of pharmaceutical consumption, drugs, pharmaceutical sales, pharmaceutical market, revenues, statistics. The annual data begins in 1960.

Long-term care resources and utilisation

This dataset provides statistics comparing long-term care resources and utilisation by country in terms of workers, beds in nursing and residential care facilities and care recipients. In this table data is expressed in different measures such as gender, age and population. The annual data begins in 1960.

Health expenditure and financing

This dataset compares countries in terms of their current and total expenditures on health by comparing how they allocate their budget with respect to different health care functions while looking at different financing agents and providers. The data covers the years starting from 1960 extending until 2010. The countries covered are Australia, Austria, Belgium, Canada, Chile, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Israel, Italy, Japan, Korea, Luxembourg, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Slovak Republic, Slovenia, Spain, Sweden, Switzerland, Turkey, United Kingdom, and United States.

Social protection

This dataset introduces the different health care coverage systems such as the government/social health insurance and private health insurance. The statistics are expressed in percentage of the population covered or number of persons. The annual data begins in 1960.

Demographic references

This dataset provides statistics regarding general demographic references in terms of population, age structure, gender, but also in term of labour force. The annual data begins in 1960.

Economic references

This dataset presents main economic indicators such as GDP and Purchasing power parities (PPP) and compares countries in terms of those macroeconomic references as well as currency rates, average annual wages. The annual data begins in 1960.

These data were first provided by the UK Data Service in November 2014.

According to Cognitive Market Research, the Global Actinic Keratosis market was USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031.

North America held the major market share for more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX % from 2024 to 2031. The Asia Pacific region is the fastest-growing market with a CAGR of XX% from 2024 to 2031 and is projected to grow at a CAGR of XX% in the future. Europe accounted for a market share of over XX% of the global revenue with a USD XX million market size. Latin America had a market share for more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031. Middle East and Africa had a market share of around XX% of the global revenue and was estimated at a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031. The Actinic Keratosis market held the highest market revenue share in 2024.

Market Dynamics of The Actinic Keratosis Market

Key Drivers for theThe Actinic Keratosis Market

The rising incidence of actinic keratosis fuels the growth of the actinic keratosis treatment market.

Actinic keratosis (AK) is one of the most common diagnoses made by dermatologists, with an estimated prevalence of 13.3% in the European population. In recent years, the incidence of AK has gone up - mainly due to an aging population, and changes in people´s behaviors which lead to increased exposure to UV radiation. It is estimated that about 28%-50% of fair-skinned individuals over 60 years of age are affected by AK, 5 and its incidence continues to increase worldwide. Actinic keratosis if left untreated may develop into a type of non-melanoma skin cancer. Therefore, the rising need for actinic keratosis treatment leads to the growing demand for actinic keratosis treatment market.

For instance, according to Cancer Research UK statistics, Non-melanoma skin cancer incidence rates are projected to rise by 14% in the UK between 2023-2025 and 2038-2040. There could be more than 262,000 new cases of non-melanoma skin cancer every year in the UK by 2038-2040, projections suggest. Source:(https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/non-melanoma-skin-cancer#heading-Zero)

For instance, according to the British Journal of Dermatology, their comprehensive meta-analysis provides an updated global prevalence rate of actinic keratosis 14%, indicating a significant worldwide disease burden. The incidence rate of actinic keratosis was found to be 1928 per 100,000 PY, emphasizing a growing public health concern. Source:(https://academic.oup.com/bjd/article/190/4/465/7331269) Thus the growing incidence of actinic keratosis cases drives the demand for its treatment thus fuelling the growth of the actinic keratosis market.

Growing awareness campaigns are likely to boost the growth of the actinic keratosis market.

A growing awareness campaign among people about the risks associated with sun exposure and the importance of early detection and treatment of skin conditions like actinic keratosis (AK) is expected to significantly boost the growth of the AK market. As more individuals become informed about the potential consequences of AK, including its link to skin cancer, they are likely to seek medical advice and treatment at earlier stages. This increased awareness not only leads to higher rates of diagnosis but also encourages proactive measures to manage or prevent AK, driving demand for effective treatment options. Additionally, heightened awareness may prompt individuals to undergo regular skin screenings, further contributing to the early detection and treatment of AK, thereby fueling market growth. For instance, in May 2023 Almirall S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, presented today the results of a survey revealing that 85% of respondents are unaware of the existence of actinic keratosis (AK). This chronic skin condition can lead to squamous cell carcinoma (SCC), the second most common form of skin cancer. The survey, conducted by Almirall with over 2,500 participants over the age of 35, aimed to understand th...

The UK mammography market, a segment of the broader global market valued at $83.72 billion in 2025 and exhibiting a robust Compound Annual Growth Rate (CAGR) of 8.74%, is poised for significant expansion over the forecast period (2025-2033). Driven by increasing breast cancer awareness, improved diagnostic imaging technologies (including digital mammography and tomosynthesis), and expanding healthcare infrastructure, the UK market is experiencing heightened demand for these essential screening and diagnostic services. The prevalence of breast cancer, a leading cause of cancer-related deaths in women, necessitates widespread screening programs, fueling market growth. Furthermore, technological advancements, such as AI-powered image analysis for improved accuracy and efficiency, are contributing to market expansion. While regulatory hurdles and high equipment costs might present challenges, the long-term outlook for the UK mammography market remains positive, driven by government initiatives promoting preventative healthcare and early detection of breast cancer. The market segmentation within the UK reflects global trends, with digital mammography systems capturing a significant share due to their superior image quality and efficiency. Hospitals and large diagnostic centers constitute the major end-users, although the role of specialty clinics is growing, facilitated by technological advancements making advanced imaging more accessible. Key players in the UK market, mirroring the global landscape, include established medical technology companies like Siemens Healthineers, GE Healthcare, and Philips, alongside specialized manufacturers focusing on mammography technology. The competitive landscape is characterized by ongoing innovation, with companies investing in research and development to improve image quality, reduce radiation exposure, and integrate AI-based analysis tools. The UK market's future growth will depend on continued investment in healthcare infrastructure, advancements in mammography technology, and effective public health initiatives promoting breast cancer awareness and early detection. We can expect further market consolidation and the emergence of innovative solutions. Recent developments include: In May 2021, the Amulet Innovality mammography system's Harmony version was introduced by Fujifilm United Kingdom (UK). The designs were created in the UK in association with the Fujifilm women's health team, and the package also comes with gantry decals and sophisticated room embellishment choices., In June 2020, Lunit revealed that Lunit INSIGHT MMG, their AI breast cancer treatment, has received CE certification and is commercially available throughout the European Economic Area, including the United Kingdom, 27 member countries of the European Union, and the European Free Trade Association.. Key drivers for this market are: Growing Burden of Breast Cancer, Technological Advancements in the Field of Breast Imaging; Investment from Various Organizations in Breast Cancer Screening Campaigns. Potential restraints include: Growing Burden of Breast Cancer, Technological Advancements in the Field of Breast Imaging; Investment from Various Organizations in Breast Cancer Screening Campaigns. Notable trends are: Hospital Segment is Expected to Hold a Significant Market Share Over the Forecast Period.

Snapshot img

Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Size 2025-2029

The epidermal growth factor receptor (EGFR) inhibitors market size is forecast to increase by USD 10.73 billion, at a CAGR of 10.5% between 2024 and 2029.

The EGFR Inhibitors Market is driven by the rising prevalence of major cancer indications, fueling the demand for effective treatment options. The market is further propelled by the expansion of research areas for the treatment of various types of cancer, including lung, breast, and colorectal cancer, leading to the development of innovative EGFR inhibitor therapies. However, high treatment costs pose a significant challenge to market growth. Despite these obstacles, the strategic landscape of the EGFR Inhibitors Market remains promising for companies seeking to capitalize on opportunities in this space. By focusing on cost-effective manufacturing and delivery models, as well as exploring collaborative partnerships and strategic acquisitions, market players can navigate the challenges and drive growth in the EGFR Inhibitors Market.

What will be the Size of the Epidermal Growth Factor Receptor (EGFR) Inhibitors Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2019-2023 and forecasts 2025-2029 - in the full report.
Request Free Sample

The EGFR inhibitor market continues to evolve as new advancements in cancer research and technology unfold. This dynamic market is driven by the ongoing exploration of cell signaling pathways and the identification of biomarkers for targeted therapy. In the realm of in-vitro diagnostics, the development of liquid biopsies enables early detection and monitoring of disease progression. Regulatory approval for new EGFR inhibitors, such as those targeting HER2 and ALK, expands treatment options for patients. Radiation therapy and treatment optimization are also key areas of focus, as researchers seek to improve overall survival and progression-free survival.

The complexities of tumor suppressor genes and tyrosine kinase inhibitors necessitate precise patient selection, as drug resistance and adverse effects can limit treatment efficacy. The integration of molecular diagnostics and companion diagnostics in precision oncology facilitates personalized medicine, ensuring that patients receive the most effective treatments based on their unique tumor profiles. Healthcare costs remain a significant concern, as the high prices of EGFR inhibitors and associated diagnostic tests can limit access to care. The development of drug delivery systems and combination therapy aims to improve treatment response while reducing costs. In the realm of in-vivo diagnostics, advances in protein expression, gene expression, epigenetic regulation, and next-generation sequencing provide valuable insights into the tumor microenvironment and cancer stem cells.

Intellectual property and health equity are also crucial considerations in the EGFR inhibitor market. Patent litigation and access to healthcare are ongoing challenges that must be addressed to ensure equitable distribution of these life-saving treatments. As research continues to advance, the EGFR inhibitor market will continue to evolve, offering new opportunities for innovation and improving patient outcomes.

How is this Epidermal Growth Factor Receptor (EGFR) Inhibitors Industry segmented?

The epidermal growth factor receptor (EGFR) inhibitors industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Indication

  Lung cancer
  Colorectal cancer
  Breast cancer
  Others


Distribution Channel

  Retail pharmacies
  Hospital pharmacies
  Online pharmacies


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  APAC

    China
    India
    Japan
    South Korea


  Rest of World (ROW)

By Indication Insights

The lung cancer segment is estimated to witness significant growth during the forecast period.

Lung cancer, a leading cause of cancer-related deaths worldwide, is characterized by the uncontrolled proliferation of cells in the lungs. This type of cancer can originate in the lungs or metastasize from other parts of the body. With an estimated annual death toll surpassing that of other major cancer indications combined, the urgency to develop effective treatment options is paramount. Two primary types of lung cancer exist: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC accounts for approximately 85% of all lung cancer cases, and its subtypes include squamous cell carcinoma, adenocarcinoma, and large cell carcinoma.

SCLC, on the other hand, accounts for around 15% of cases and is often more aggressive. Targeted therapies, such